Tarceva

In the US, Tarceva (erlotinib systemic) is a member of the drug class EGFR inhibitors and is used to treat Non-Small Cell Lung Cancer, Pancreatic Cancer and Renal Cell Carcinoma.

US matches:

• Tarceva

UK matches:

• Tarceva 25mg, 100mg and 150mg Film-Coated Tablets (SPC)

Ingredient matches for Tarceva

Erlotinib

Erlotinib is reported as an ingredient of Tarceva in the following countries:

• Bulgaria


• Colombia


• Ecuador


• Slovakia


• Taiwan

Erlotinib hydrochloride (a derivative of Erlotinib) is reported as an ingredient of Tarceva in the following countries:

• Argentina


• Australia


• Austria


• Belgium


• Bosnia & Herzegowina


• Canada


• China


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Finland


• France


• Georgia


• Germany


• Hong Kong


• Hungary


• Indonesia


• Ireland


• Israel


• Italy


• Japan


• Mexico


• Netherlands


• New Zealand


• Norway


• Oman


• Philippines


• Poland


• Portugal


• Romania


• Serbia


• Singapore


• Slovenia


• Spain


• Sweden


• Switzerland


• Thailand


• United Kingdom


• United States


• Venezuela

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.